ClinicalTrials.gg
CompletedNCT04756310Updated Feb 16, 2021

Study of Nutritional Supplementation in Patients With Unilateral Wet AMD

An interventional study of Retilut and Theavit in Wet Macular Degeneration, sponsored by Laboratorios Thea, Spain. Completed at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Laboratorios Thea, Spain · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Nov 2014, registered Dec 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Wet Macular Degeneration with a site in Spain — 4 open to participants now, 5 under way, 5 of them phase 3. Wet Macular Degeneration · Spain.

Enrollment
12th of 14
109 · median 609
Started
2014
the only one that year
No phase
Only one
of the 14
Registered
2nd of 14
by date
Lead sponsor
1 of 14
Laboratorios Thea, Spain

Among the 14 studies in Wet Macular Degeneration with a site in Spain, this one is the 12th largest by enrollment, is the only one that started in 2014, is the only one with no phase, and was the 2nd registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

4 of the 14 studies in Wet Macular Degeneration with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Wet Macular Degeneration with a site in Spain, or all of them as a file.
02

Study summary

Retinal diseases are currently the leading cause of legal blindness in the developed world. Among these disorders, age-related macular degeneration (AMD) is one of the most prevalent conditions in individuals over 55 years of age. Late AMD, the most severe presentation of the disease, clinically manifests as either geographic atrophy (dry form) or choroidal neovascularization (CNV) (wet form). Although patients with wet AMD only represent 10% of the total cases, CNV is the main and most serious cause of central vision loss. At present, the treatment of wet AMD comprises intraocular injections of certain antiangiogenic agents which act by blocking VEGF (vascular endothelial growth factor). No effective treatment is yet available for dry AMD, though the AREDS (Age-Related Eye Disease Study) has shown that the administration of antioxidant supplements is able to slow progression of the disease. Such vitamin supplements are also indicated in patients who already have severe AMD (both exudative and atrophic) in one eye, since the risk of progression in these cases is high.

Recent studies involving new antioxidant and antiangiogenic molecules such as resveratrol, present in grapes and wine, have also revealed great efficacy in slowing the progression of advanced AMD. Hydroxytyrosol is another polyphenol with important antioxidant and antiinflammatory effects in the RPE.

Considering the above, the present randomized, multicenter interventional study involving Spanish and Portuguese patients with unilateral wet AMD was designed to compare the effects of two different nutritional supplements: one containing the antioxidants and minerals recommended by the AREDS at doses that can be used in the European Union (Theavit), and the other comprising these same substances plus omega-3 fatty acids (lipidic antioxidant), lutein (pigment protecting against light-induced damage) and resveratrol (antioxidant and antiangiogenic agent) (Retilut).

Read the detailed description

Retinal diseases are currently the leading cause of legal blindness in the developed world. Among these disorders, age-related macular degeneration (AMD) is one of the most prevalent conditions in individuals over 55 years of age. In the United States, the prevalence of AMD varies from 0.5% at 55 years to 7% in people over 75 years. These data are clearly a cause for concern, in view of the aging of the population in developed countries. In Spain, a country with one of the greatest population aging problems, AMD affects 1.7% of all people over 50 years, and the incidence increases with age, reaching 18.5% among those over 85 years. AMD is characterized by progressive destruction of the central region of the retina (macula), resulting in central vision loss. While this does not lead to complete blindness, the associated impairment of autonomy has a very strong impact upon patient quality of life. AMD is a multifactorial disease - a fact that makes it difficult to establish the underlying etiology. In this sense, although only age is accepted as the principal factor associated to the development of AMD, other factors such as smoking, diet, oxidative stress, arterial hypertension or obesity have been extensively investigated in the context of the disease.

Late AMD, the most severe presentation of the disease, clinically manifests as either geographic atrophy (dry form) or choroidal neovascularization (CNV) (wet form). Although patients with wet AMD only represent 10% of the total cases, CNV is the main and most serious cause of central vision loss. At present, the treatment of wet AMD comprises intraocular injections of certain antiangiogenic agents such as ranibizumab, bevacizumab, aflibercept, etc., which act by blocking vascular endothelial growth factor (VEGF). No effective treatment is yet available for dry AMD, though the Age-Related Eye Disease Study (AREDS) has shown that the administration of antioxidant supplements is able to slow progression of the disease. Such vitamin supplements are also indicated in patients who already have severe AMD (both exudative and atrophic) in one eye, since the risk of progression in these cases is high.

The AREDS, sponsored by the National Eye Institute, was started in 1998 with the purpose of evaluating the effect of high-dose antioxidants (vitamins C and E, and beta-carotene) and minerals (zinc) upon the course of the disease. The results of the study showed that high levels of antioxidants and zinc significantly reduced the risk of progression towards advanced stages of AMD by 25%, and of vision loss by 19%. However, due to safety reasons, the doses used in the AREDS cannot be administered in the European Union, since they exceed the Recommended Daily Allowances (RDA). Therefore, the standard clinical practice is to use these substances in patients with high risk AMD as nutritional supplements at the usual RDAs. However, no interventional studies demonstrating the effects of these supplements have been carried out.

Following publication of the AREDS I, certain dietary intake studies suggested the importance of other molecules such as omega-3 fatty acids (DHA, EPA, DPA) and lutein / zeaxanthin. The AREDS work group therefore decided to conduct a new study including both nutrients in addition to those already evaluated (antioxidants and zinc). Lutein exerts an antioxidative effect, can act as a blue light filter, and moreover has antiinflammatory properties. This latter effect is especially important, considering that AMD is a disease secondary to a low-grade chronic inflammatory process of the retinal pigment epithelium (RPE). In addition to their antioxidant and antiinflammatory effects, the omega-3 fatty acids have important antiangiogenic properties, as evidenced both by in vitro and in vivo studies.

Recent studies involving new antioxidant and antiangiogenic molecules such as resveratrol, present in grapes and wine, have also revealed great efficacy in slowing the progression of advanced AMD. Hydroxytyrosol is another polyphenol with important antioxidant and antiinflammatory effects in the RPE.

Considering the above, the present randomized, multicenter interventional study involving Spanish and Portuguese patients with unilateral wet AMD was designed to compare the effects of two different nutritional supplements: one containing the antioxidants and minerals recommended by the AREDS at doses that can be used in the European Union (Theavit), and the other comprising these same substances plus omega-3 fatty acids (lipidic antioxidant), lutein (pigment protecting against light-induced damage) and resveratrol (antioxidant and antiangiogenic agent) (Retilut).

Study Design: A randomized, double-blind, multicenter interventional nutritional dose study was designed. The patient follow-up period will last 24 months. The estimated patient enrollment period will cover 9 months, and analysis of the results will be completed four months after the end of the follow-up period. The estimated total duration of the project will be between 52 months.

Study Subjects:

These patients from the different Spanish populations will be enrolled making use of the infrastructure afforded by the RETICS network, "Eye disease related to aging, vision quality and quality of life" (RD07/0062 subproject Retina). All patients will be 50 years old or more, and written informed consent will be obtained in all cases, together with authorization to enter their data in a database (data protection consent following the criteria of the Ethics Committees of each of the participating centers).

On the baseline visit, the patients will undergo a complete ophthalmological evaluation, and plasma will be collected for posterior analysis of several biochemical parameters.

Those patients who meet the inclusion criteria and none of the exclusion criteria will start nutritional supplementation for two years (2 daily capsule, nutritional dose) with one of the nutritional supplements. The study will be carried out on a simple-blind basis, even the patient knows the origin of the treatment, the ophthalmologist conducting follow-up will not know the composition of the provided supplement. Accordingly, the boxes and capsules will be adequately masked. The blisters with the nutritional supplements will be delivered to each patient at the inclusión visit (Day 0), and the empty blisters are to be returned as an initial measure of treatment compliance. Patient follow-up will take place every 6 months (Day 0, Month 6, Month 12, Month 18, Month 24), and will comprise a complete ophthalmological evaluation, with the registry of any ophthalmological adverse events. The appearance of such adverse events will be a secondary study endpoint, and is defined as the appearance of choroidal neovascularization in the fellow eye. First objective will be the measure of the change in the best corrected visual acuity (BCVA) in the study eye. Blood samples will be collected at Day 0, Month 12 and Month 24 for biochemical analysis (Luminex® markers, omega 3, lutein and zeaxanthin profile and plasma REDOX status) representing also a secondary study endpoints.

Ophthalmological examination:

  • Visual acuity will be determined with the ETDRS system at a distance of four meters with the best optic correction.
  • Anterior segment biomicroscopy study to discard opacification of the media. -Biomicroscopic funduscopy with +78/+90D lens.
  • Digital retinography of the ocular fundus, red-free light photography of the fundus, and autofluorescence photography of the fundus under maximum pharmacologic mydriasis to ensure maximum image quality; a minimum of three examinations with photographs at 30/35° will be obtained.
  • The follow-up of neovascularization will be carried out by fluorescein angiography and optical coherence tomography (OCT). The presence of subretinal and/or intraretinal fluid will be taken as a sign of wet AMD in OCT.

Biochemical analysis:

The plasma of the patients both on Day 0 and at the end of the study will be subjected to the following determinations:

  • Analysis of the lipid profile (omega 3).
  • Evaluation of the systemic oxidative condition based on total antioxidant capacity assay.
  • Determination of lutein levels by HPLC.
  • Detection of the main inflammatory and oxidative stress markers and/or vascular factors in plasma, based on Luminex® technology (affymetrix): VEGF-A, IL-1 beta, IL-6, IL-8, Eotaxin-2 (CCL24), HGF, PDGF, MCP-1, TNF-alpha and FGF.
03

Conditions studied

  • Wet Macular Degeneration

Keywords

  • AMD
  • Food Supplement
  • Antioxidant effect
  • Antiangiogenic effect
  • resveratrol
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged ≥ 50 years.
  2. Presence of unilateral choroidal neovascularisation or any of its clinical manifestations, such as disciform scars, subretinal hemorrhage, retinal pigment epithelium detachment associated to subretinal fluid and/or subretinal hemorrhage (stage V of the modified AREDS classification; AREDS, J.M. Seddon; IOVS 2009).
  3. Patients who understand the conditions and particularities of the study and have given their written to participation in the trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with myopia > 6 dioptres.
  2. Presence of posterior pole anomalies which can give rise to choroidal neovascularisation: nevi, angioid streaks, central serous choroidopathy, heredodegenerative retinal diseases, myopic choroidosis, diabetic retinopathy and choroiditis.
  3. Media opacification precluding adequate assessment of the ocular fundus.
  4. Patients who in the opinion of the investigator are very likely to not be able or not want to continue participating in the study.
  5. Women of who do not use a medically acceptable and highly effective method (i.e., hormone implants, oral or parenteral contraceptives, together with condoms, certain intrauterine devices) from the inclusion visit and throughout the study treatment periods, up until two weeks after the study. women (two years without menstruation) require no contraceptive method.
  6. Patients having participated in any other treatment efficacy protocol in the previous three months.
  7. Patients who will be participating in any other treatment efficacy protocol concomitant to the present study.
  8. Patients using any type of nutritional supplement in the month before the screening visit.
  9. Suspected or confirmed illegal drug abuse.
  10. Incapacity of the patient and/or relatives to understand the study procedures, and thus inability to give .
  11. Non-compliers, i.e., patients who fail to report to the follow-up visits or whose life style interferes with the protocol.
  12. Patients under legal custody.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
109 participants (actual)

Study arms

  • Placebo comparator
    Control

    Patients receiving Theavit food supplement considered as a placebo treatment for AMD condition. Two capsules/day before breakfast each day for 2 years

    Dietary Supplement: Theavit

  • Experimental
    Retilut

    Patients receiving Retilut food supplement. Two capsules/day before breakfast each day for 2 years

    Dietary Supplement: Retilut

Interventions

  • Dietary supplementRetilut

    antioxidants, antiangiogenic, antiinflammatory micronutrients

  • Dietary supplementTheavit

    antioxidants micronutrients

    Also known as: food supplement

06

What researchers measure

Primary outcomes

  1. Best correct visual acuity (BCVA)

    Variation in BCVA in the studied eye.

    Time frame: Comparison will be made of best visual acuity recorded in Month 12 versus that recorded on the baseline visit (Day 0).

  2. Best correct visual acuity (BCVA)

    Variation in BCVA in the studied eye.

    Time frame: Comparison will be made of best visual acuity recorded in Month 24 versus that recorded on the baseline visit (Day 0).

Secondary outcomes

  1. Inflammatory markers

    VEGF-A, IL-1 beta, IL-6, IL-8, Eotaxin-2 (CCL24), HGF, PDGF, MCP-1, TNF-alfa and FGF.

    Time frame: Determination will be made of the mean values obtained on visits Month 12 with respect to the recorded baseline values on visit Day 0

  2. Lipid blood profile

    Biochemical blood profile: Omega-3 lipid profile

    Time frame: Determination will be made of the mean values obtained on visits Month 12 with respect to the recorded baseline values on visit Day 0

  3. Lipid blood profile

    Biochemical blood profile: Omega-3 lipid profile

    Time frame: Determination will be made of the mean values obtained on visits Month 24 with respect to the recorded baseline values on visit Day 0

  4. Carotenoid profile

    Biochemical blood profile: lutein and zeaxantine values

    Time frame: Determination will be made of the mean values obtained on visits Month 12 with respect to the recorded baseline values on visit Day 0

  5. Carotenoid profile

    Biochemical blood profile: lutein and zeaxantine values

    Time frame: Determination will be made of the mean values obtained on visits Month 24 with respect to the recorded baseline values on visit Day 0

  6. Adverse Events

    Determination and classification of simple and serious adverse events related or not to the study treatment and which appear in the contralateral eye.

    Time frame: The percentage of these events will be the cumulative value on visits Month 6 in the study treatment group versus the control group.

  7. Adverse Events

    Determination and classification of simple and serious adverse events related or not to the study treatment and which appear in the contralateral eye.

    Time frame: The percentage of these events will be the cumulative value on visits Month 12 in the study treatment group versus the control group.

07

Study locations

9 sites
  • AIBILI
    Celas, Coimbra 3000-548, Portugal
  • Instituto de Retina e Diabetes Ocular de Lisboa (IRL)
    Lisboa, 1050-085, Portugal
  • Complexo Hospitalario Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
  • Miguel Servet University Hospital
    Zaragoza, Aragon 50009, Spain
  • Hospital Dos de Maig
    Barcelona, Catalunya 08025, Spain
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Vall d´Hebrón
    Barcelona, 08035, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Policlínico Universitario La Fe
    Valencia, 46026, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Apr 2018, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2015
First posted
Feb 16, 2021
StartActual
Nov 2014
Primary completionActual
Apr 2018
CompletionActual
Apr 2018
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04756310
Lead sponsor
Laboratorios Thea, Spain
Collaborators
Alpha Bioresearch S.L., Investigación Estadística
Responsible party
Sponsor
First posted
Feb 16, 2021
Start date
Nov 2014
Primary completion
Apr 2018
Completion
Apr 2018
Last update
Feb 16, 2021

Study contacts

Alfredo García-Layana, MD
study director · Clínica Universidad de Navarra
Roberto Gallego-Pinazo, MD
principal investigator · Hospital Universitario Politécnico La Fe
Emiliano Hernández-Galilea, MD
principal investigator · University of Salamanca
Miguel Ángel Zapata-Victori, MD
principal investigator · Hospital Universitario Vall d´Hebron
Maximino Abraldes, MD, PhD
principal investigator · Complexo Hospitalario Universitario de Santiago de Compostela
Rufino Silva, MD, PhD,FEBO
study director · Association for Innovation and Biomedical Research on Light and Image
Joao Nascimento, MD
principal investigator · Instituto de Retina e Diabetes Ocular de Lisboa
Jose J Escobar-Barranco, MD
principal investigator · Hospital Dos de Maig
Pilar Calvo, Md, PhD
principal investigator · Miguel Servet University Hospital, Zaragoza

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion